TriHealth has formed a new partnership with RevealDx, a Seattle-based medical imaging AI company, to enhance the precision of lung nodule diagnosis and management across its network.

Lung nodules are commonly detected on imaging scans, and while most are benign, a small percentage may indicate early-stage lung cancer. Early and accurate risk assessment is critical to guide treatment decisions. TriHealth, based in Cincinnati, Ohio, has been expanding its lung cancer program, which already includes robotic bronchoscopy for more precise tissue sampling.

The collaboration with RevealDx adds AI-driven decision support to the program. RevealDx’s technology analyzes CT images to assess the malignancy risk of lung nodules without requiring tissue or blood samples. The software is built on radiomics and machine learning models that have undergone validation in clinical research.
The partnership will begin with a clinical study designed to evaluate how RevealDx’s AI performs in a real-world setting. The study will track both clinical outcomes and operational impacts, focusing on high-volume chest CT environments and active lung cancer screening programs.

TriHealth has also integrated technologies from Riverain Technologies, which provides tools to enhance CT-based nodule detection, and Thynk Health, which supports nodule tracking and outcomes reporting.

“For decades, lung nodule assessment has followed a pattern of detection, measurement, and repeated scanning—often resulting in delayed diagnosis of lung cancer,” said Dr. Doug Adams of TriHealth. “AI tools now offer the potential to deliver critical insights at the very first scan. When paired with AI-driven informatics, this represents a significant step forward. We’re eager to study how these tools improve care in a real-world setting.”

The study will include contributions from RevealDx, Thynk Health, and Riverain Technologies, with RevealDx providing financial support.

Rad Oncology Homepage